GLP-1vsMazdutide

GLP-1 (glucagon-like peptide 1) is the native incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. It is the endogenous molecule that all GLP-1 receptor agonist drugs (semaglutide, liraglutide, etc.) are designed to mimic. Understanding native GLP-1 is essential to understanding the entire drug class built upon its biology.

Upon release, GLP-1 binds to GLP-1 receptors (GLP-1R) — G protein-coupled receptors expressed on pancreatic beta cells, the GI tract, the heart, the kidneys, and critically, the brain. In the pancreas, GLP-1R activation stimulates adenylyl cyclase, raising intracellular cAMP levels, which potentiates glucose-stimulated insulin secretion. This glucose-dependence is a key safety feature — GLP-1 only promotes insulin release when blood sugar is elevated, minimizing hypoglycemia risk. Simultaneously, GLP-1 suppresses glucagon secretion from alpha cells, further reducing hepatic glucose output.

In the brain, GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate appetite suppression and satiety. GLP-1 also activates vagal afferents to slow gastric emptying, prolonging nutrient absorption and post-meal satiety. The critical limitation of native GLP-1 is its extremely rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids within 1-2 minutes, rendering it inactive. This ultra-short half-life is why pharmaceutical GLP-1 analogues require structural modifications (albumin binding, DPP-4 resistance) to achieve clinically useful durations of action.

Mazdutide is a dual-receptor agonist that activates both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure. The GLP-1 component functions similarly to other GLP-1 agonists — binding to receptors in the hypothalamus to reduce hunger, stimulating glucose-dependent insulin secretion from pancreatic beta cells, and slowing gastric motility to prolong post-meal satiety.

The glucagon receptor component distinguishes mazdutide from pure GLP-1 agonists. Glucagon binding in the liver activates adenylyl cyclase, increasing cAMP and activating protein kinase A, which phosphorylates key enzymes in fatty acid oxidation and ketogenesis. This drives the liver to burn stored fat as fuel rather than accumulate it — a mechanism with direct therapeutic relevance for patients with metabolic-associated fatty liver disease (MAFLD). In adipose tissue, glucagon signaling promotes lipolysis and may activate thermogenic programs in brown and beige fat cells.

The engineering challenge in dual GLP-1/glucagon agonists is balancing the hyperglycemic effect of glucagon against the glucose-lowering effects of GLP-1. Mazdutide achieves this by tuning the relative receptor affinities so that GLP-1-mediated insulin secretion offsets glucagon-driven glucose production, resulting in net glycemic improvement alongside enhanced fat oxidation and energy expenditure.